Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40165410.
- Also identified by DOI 10.1093/cid/ciaf164.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated infectious complications and the associated risk factors in 181 patients undergoing T-cell engagers for malignancies. Infections were primarily observed in patients with hematological diseases or heavily pre-treated. Mortality due to infectious complications was 2.8%. Concomitant medications with corticosteroids or tocilizumab did not significantly impact the incidence of infections.
Medical subject headings
- Neoplasms
- T-Lymphocytes
- Immunotherapy
- Infections